Alector, Inc. Common Stock (ALEC) Stock
Key stats
- Market cap
- $209.92M
- Price / Earnings ratio
- -1.8x
- EPS (TTM)
- -$1.10
- Volume
- Loading
- 52-week high
- $3.40
- 52-week low
- $1.09
Source: third-party data provider, as of October 16, 2026
Compare with ALEC
Recent news

Alector Maps Brain-Delivery Pipeline for Alzheimer's, Parkinson's Therapies
Alector Maps Brain-Delivery Pipeline for Alzheimer's, Parkinson's Therapies
ALEC

Stocktwits Biotech Dealmaker — Viatris And GE Healthcare Buy What They Can Sell; Biohaven And Alector Sell Rights
Stocktwits Biotech Dealmaker — Viatris And GE Healthcare Buy What They Can Sell; Biohaven And Alector Sell Rights
ALEC

Alector soars as Roche licenses Parkinson's therapy for up to $1.27 billion
Alector soars as Roche licenses Parkinson's therapy for up to $1.27 billion
ALEC

Alector (ALEC) Reports Q2 Loss, Tops Revenue Estimates
Alector (ALEC) Reports Q2 Loss, Tops Revenue Estimates
ALEC
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 45.12
- MACD 12/26/9
- -0.04
- EMA 9 of MACD
- -0.04
- MACD histogram
- 0.01
- SMA 50
- $2.09
- Price below SMA 50
- EMA 50
- $2.00
- Price below EMA 50
- SMA 200
- $2.01
- Price below SMA 200
- EMA 200
- $1.95
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 14, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Sell
Based on 2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Alector Maps Brain-Delivery Pipeline for Alzheimer's, Parkinson's Therapies
Alector Maps Brain-Delivery Pipeline for Alzheimer's, Parkinson's Therapies
ALEC

Stocktwits Biotech Dealmaker — Viatris And GE Healthcare Buy What They Can Sell; Biohaven And Alector Sell Rights
Stocktwits Biotech Dealmaker — Viatris And GE Healthcare Buy What They Can Sell; Biohaven And Alector Sell Rights
ALEC

Alector soars as Roche licenses Parkinson's therapy for up to $1.27 billion
Alector soars as Roche licenses Parkinson's therapy for up to $1.27 billion
ALEC

Alector (ALEC) Reports Q2 Loss, Tops Revenue Estimates
Alector (ALEC) Reports Q2 Loss, Tops Revenue Estimates
ALEC

Alector and GSK partnership to end after dementia, Alzheimer's drug failures
Alector and GSK partnership to end after dementia, Alzheimer's drug failures
ALEC

Alector (ALEC) Reports Q1 Loss, Lags Revenue Estimates
Alector (ALEC) Reports Q1 Loss, Lags Revenue Estimates
ALEC

Will Alector (ALEC) Report Negative Q1 Earnings? What You Should Know
Will Alector (ALEC) Report Negative Q1 Earnings? What You Should Know
ALEC

Alector (ALEC)'s Technical Outlook is Bright After Key Golden Cross
Alector (ALEC)'s Technical Outlook is Bright After Key Golden Cross
ALEC

Wall Street Turns Bullish on HIMS, TDOC and ALEC as Partnerships Reshape Risk Profiles
Wall Street Turns Bullish on HIMS, TDOC and ALEC as Partnerships Reshape Risk Profiles
ALEC

Alector (ALEC) Reports Q4 Loss, Beats Revenue Estimates
Alector (ALEC) Reports Q4 Loss, Beats Revenue Estimates
ALEC
News tone: automated (AI) classification of the article's content, not a price prediction.
About Alector, Inc. Common Stock
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Arnon Rosenthal Ph.D. | Co-Founder, CEO & Director | 1956 |
| Mr. Neil Berkley M.B.A., M.S. | CFO & Chief Business Officer | 1974 |
| Ms. Katie Hogan | Senior Director of Corporate Communication & Investor Relations | — |
| Ms. Danielle Pasqualone J.D., Ph.D. | General Counsel | — |
| Ms. Clare Hunt M.B.A. | Chief People & Places Officer | — |
| Dr. Hua Long DABT, Ph.D. | Senior VP & Head of Research | — |
| Dr. Caiyan Li Ph.D. | Head of Clinical Development & Data Science | — |
| Dr. Eric Brown Ph.D. | Director of Antibody Discovery & Protein Engineering | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of October 16, 2026
Technical indicators
- RSI 14
- 45.12
- MACD 12/26/9
- -0.04
- EMA 9 of MACD
- -0.04
- MACD histogram
- 0.01
- SMA 50
- $2.09
- Price below SMA 50
- EMA 50
- $2.00
- Price below EMA 50
- SMA 200
- $2.01
- Price below SMA 200
- EMA 200
- $1.95
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 14, 2026. Technical data, not a recommendation.
Analyst views
2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $3.00
- Average
- $5.50
- High
- $8.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +23.4 | -2.7 | -6.3 | -8.5 | -2.9 | -24.9 | +49.7 | -22.9 | +1.1 |



